Home  >  News
Eppen_CellXpert_Feb25
Waters_Ebook_Dec24
you can get e-magazine links on WhatsApp. Click here
Corporate + Font Resize -

JB Pharma reports revenue growth of 14% to Rs. 963 crore in Q3 FY25 net profit increased by 22% to Rs. 162 crore

Our Bureau, Mumbai
Wednesday, February 5, 2025, 12:20 Hrs  [IST]

JB Chemicals & Pharmaceuticals ltd, one of the fastest growing pharmaceutical companies in India, announced its financial results for the quarter ended 31st December, 2024.
 
JB Pharma recorded revenue of Rs. 963 crore in the third quarter of FY25 registering growth of 14% from Rs. 845 crore in Q3 FY24. Operating EBITDA (earnings before interest depreciation and taxes) improved by 15% to Rs. 270 crore. Profit after taxes registered strong growth of 22 per cent to Rs. 162 crore vs Rs. 134 crore in Q3 FY24. Operating EBITDA is after excluding non-cash ESOP charge.
 
Commenting on the financial results, Nikhil Chopra, CEO and whole time director, JB Pharma mentioned, “JB has delivered consistent growth over last few years even amidst a volatile macroeconomic environment. This has been enabled by our mix of businesses and markets, specifically our focus on India branded formulations, CDMO, and select international markets which play to our strengths, with limited revenues in countries that might present trade-related or economic volatility challenges.
 
JB is well-positioned to deliver continued growth going forward as well. The strategy and levers are well-defined, and we have a strong team that will execute. Our India business continues to drive market beating growth led by chronic business and progressive portfolio within the acute segment. Our export business continues to be steady with sequential improvement witnessed in our CDMO business. While the growth run-rate of JB’s quarterly performance has been maintained, we have also improved our operating margins driven by product mix and efficiency initiatives.
 
Advancement of various new projects in the CDMO business will flow through into growth numbers in the near to medium term, and we have a good pipeline of future product commercialization opportunities in international business which will deliver continued growth.”
 
For the first nine months of the financial year 2024-25, the company recorded revenue of Rs. 2,969 crore as compared to Rs. 2,622 crore, registering growth of 13%. Operating EBITDA (earnings before interest depreciation and taxes) increased by 16 per cent to Rs. 846 crore as compared to Rs. 729 crore. Profit after tax registered growth of 20 per cent to Rs. 514 crore vs Rs. 426 crore in 9M FY24.
 
J B Pharma established in 1976 is one of the fastest growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for the majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has six brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA.
 
Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. The company ranks amongst the top 5 manufacturers globally in medicated and herbal lozenges. It has eight state of the art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Avians_2025
Asia_Lab_Expo2025
chemexpoindia
ana-Lab-India_25
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram